// App-Quantinova.ai

e13577 : Pharmacodynamic monitoring of DNA damage biomarkers in circulating tumor cells (CTCs) to assess the mechanism of action of the topoisomerase-1 (Topo1) inhibitor, NKTR-102.

Researchers

Presenter

  • Sujita Sukumaran

Principal Investigators

  • Christopher Neal

  • Jacky Woo

  • Vladislava O. Melnikova

  • Kenna Lynn Anderes

  • Christine Taylor Brew

  • Darren W. Davis

  • Ute Hoch

Medical Centers

  • ApoCell, Inc., Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Breast cancer type 2 susceptibility protein

  • Circulating tumor cells

  • RAD51 Recombinase

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • etirinotecan pegol

  • SN38

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved